Ukr.Biochem.J. 2019; Volume 91, Issue 2, Mar-Apr, pp. 19-27

doi: https://doi.org/10.15407/ubj91.02.019

Preparation of highly-concentrated autologous platelet-rich plasma for biomedical use

01.04.2019   Uncategorized   No comments

V. Chernyshenko1, K. Shteinberg2, N. Lugovska1, M. Ryzhykova1,
T. Platonova1, D. Korolova1, E. Lugovskoy1

1Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: bio.cherv@gmail.com;
2‘Dr. Zapolska Clinic’, Kyiv, Ukraine

Received: 21 December 2018; Accepted: 20 March 2019

Cell therapy with platelets is a widely accepted approach for wound healing and tissue regeneration in medicine. However, with most available methods poorly concentrated platelet suspensions (up to 0.3∙106 1/µl) or suspensions of mostly inactivated or lost platelets are obtained. In this study, we aimed to develop a simple and effective method for preparing a suspension of native and resting platelets with over 1∙106 1/µl. Platelet-rich plasma (PRP) was obtained from fresh blood of healthy donors (n = 5) collected using different amounts of heparin as the anticoagulant. Samples of PRP were spun down and re-suspended in auto­logous blood plasma. Count and vitality of platelets in each sample were determined by aggregation study on the Solar AP2110 aggregometer. Platelet shape and cytoplasmic granularity that indicate the nativity of platelets were monitored on the COULTER EPICS XL Flow Cytometer. This study of aggregation of platelets in PRP obtained using various amounts of heparin allowed us to reduce final concentrations to the amount that effectively prevented clotting and did not affect platelet reactivi­ty (5 U/ml). PRP concentrated 5 times with a total concentration of cells of 1∙106 1/µl was able to be activated by adenosine diphosphate (ADP) (aggregation rate 54 ± 7%). The amount of cells with altered shape and granularity in concentrated suspension was not higher than 20%. This finding means that the platelets would still be able to release a number of growth factors and other biologically active compounds after stimulation or injection into tissue during cell therapy. The decrease in heparin concentrations also minimizes haemorrhage in the injection site supporting biomedical use of the suspension. A simple and effective method for preparation of highly-concentrated PRP (1.2∙106 1/µl) for biomedical use was developed. Aggregometry and flow cytometry proved that obtained platelets were resting and able to be activated. Being autologous, the preparation can be widely used for cell therapy without additional precautions.

Keywords: , , , ,

References:

  1. Dhillon RS, Schwarz EM, Maloney MD. Platelet-rich plasma therapy – future or trend? Arthritis Res Ther. 2012 Aug 8;14(4):219. PubMed, PubMedCentral, CrossRef
  2. Galliera E, Corsi MM, Banfi G. Platelet rich plasma therapy: inflammatory molecules involved in tissue healing. J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2 Suppl 1):35S-42S. PubMed
  3. Arshdeep, Kumaran MS. Platelet-rich plasma in dermatology: boon or a bane? Indian J Dermatol Venereol Leprol. 2014 Jan-Feb;80(1):5-14. PubMed,CrossRef
  4. Singhal P, Agarwal S, Dhot PS, Sayal S. Efficacy of platelet-rich plasma in treatment of androgenic alopecia. Asian J Transfus Sci. 2015 Jul-Dec;9(2):159-62.  PubMed, PubMedCentral, CrossRef
  5. Frautschi RS, Hashem AM, Halasa B, Cakmakoglu C, Zins JE. Current Evidence for Clinical Efficacy of Platelet Rich Plasma in Aesthetic Surgery: A Systematic Review. Aesthet Surg J. 2017 Mar 1;37(3):353-362.  PubMed, CrossRef
  6. Glynn LG, Mustafa A, Casey M, Krawczyk J, Blom J, Galvin R, Hannigan A, Dunne CP, Murphy AW, Mallen C. Platelet-rich plasma (PRP) therapy for knee arthritis: a feasibility study in primary care. Pilot Feasibility Stud. 2018 Jul 4;4:93. PubMed, PubMedCentral, CrossRef
  7. Intini G. The use of platelet-rich plasma in bone reconstruction therapy. Biomaterials. 2009 Oct;30(28):4956-66. PubMed, CrossRef
  8. Chicharro-Alcántara D, Rubio-Zaragoza M, Damiá-Giménez E, Carrillo-Poveda JM, Cuervo-Serrato B, Peláez-Gorrea P, Sopena-Juncosa JJ. Platelet Rich Plasma: New Insights for Cutaneous Wound Healing Management. J Funct Biomater. 2018 Jan 18;9(1). pii: E10. PubMed, PubMedCentral, CrossRef
  9. Keene DJ, Alsousou J, Willett K. How effective are platelet rich plasma injections in treating musculoskeletal soft tissue injuries? BMJ. 2016 Feb 17;352:i517. PubMed, CrossRef
  10. Bell KJ, Fulcher ML, Rowlands DS, Kerse N. Impact of autologous blood injections in treatment of mid-portion Achilles tendinopathy: double blind randomised controlled trial. BMJ. 2013 Apr 18;346:f2310. PubMed, PubMedCentral, CrossRef
  11. Grassi A, Napoli F, Romandini I, Samuelsson K, Zaffagnini S, Candrian C, Filardo G. Is Platelet-Rich Plasma (PRP) Effective in the Treatment of Acute Muscle Injuries? A Systematic Review and Meta-Analysis. Sports Med. 2018 Apr;48(4):971-989. PubMed, CrossRef
  12. Fitzpatrick J, Bulsara MK, McCrory PR, Richardson MD, Zheng MH. Analysis of Platelet-Rich Plasma Extraction: Variations in Platelet and Blood Components Between 4 Common Commercial Kits. Orthop J Sports Med. 2017 Jan 3;5(1):2325967116675272. PubMed, PubMedCentral, CrossRef
  13. Chahla J, Cinque ME, Piuzzi NS, Mannava S, Geeslin AG, Murray IR, Dornan GJ, Muschler GF, LaPrade RF. A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. J Bone Joint Surg Am. 2017 Oct 18;99(20):1769-1779.  PubMed, CrossRef
  14. Gómez LA, Escobar M, Peñuela O. Standardization of a Protocol for Obtaining Platelet Rich Plasma from blood Donors; a Tool for Tissue Regeneration Procedures. Clin Lab. 2015;61(8):973-80. PubMed, CrossRef
  15. Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, Lussana F, Pugliano MT, Michelson AD. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013; 11(6):1183-1189.  PubMed, CrossRef
  16. Chernyshenko V, Petruk N, Korolova D, Kasatkina L, Gornytska O, Platonova T, Chernyshenko T, Rebriev A, Dzhus O, Garmanchuk L, Lugovskoy E. Antiplatelet and anti-proliferative action of disintegrin from Echis multisquamatis snake venom. Croat Med J. 2017 Apr 14;58(2):118-127. PubMed, PubMedCentral, CrossRef
  17. Korolova DS, Chernyshenko TM, Gornytska OV, Chernyshenko VO, Platonova TN. Meizothrombin preparation and its role in fibrin formation and platelet aggregation. Adv Biosci Biotechnol. 2014;5(7):588-595. CrossRef
  18. Gryshchuk V, Galagan N. Silica Nanoparticles Effects on Blood Coagulation Proteins and Platelets. Biochem Res Int. 2016;2016:2959414. PubMed, PubMedCentral, CrossRef
  19. Chernyshenko V, Platonova T, Makogonenko Y, Rebriev A, Mikhalovska L, Chernyshenko T, Komisarenko S. Fibrin(ogen)olytic and platelet modulating activity of a novel protease from the Echis multisquamatis snake venom. Biochimie. 2014 Oct;105:76-83. PubMed, CrossRef
  20. Korol’ova DS, Chernyshenko VO, Hornyts’ka OV, Platonova TM. Influence of prothrombin cleavage products on platelet activation and aggregation. Ukr Biokhim Zhurn. 2009 Sep-Oct;81(5):58-65. (In Ukrainian). PubMed
  21. do Amaral RJ, da Silva NP, Haddad NF, Lopes LS, Ferreira FD, Filho RB, Cappelletti PA, de Mello W, Cordeiro-Spinetti E, Balduino A. Platelet-Rich Plasma Obtained with Different Anticoagulants and Their Effect on Platelet Numbers and Mesenchymal Stromal Cells Behavior In Vitro. Stem Cells Int. 2016;2016:7414036. PubMed, PubMedCentral, CrossRef
  22. Hua L, Lai G, Zhenjun L, Guie M.The study of anticoagulants selection in platelet-rich plasma preparation. Zhonghua Zheng Xing Wai Ke Za Zhi. 2015 Jul;31(4):295-300. (In Chinese).
  23. Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018 Jan;4(1):18-24. PubMed, PubMedCentral, CrossRef
  24. Laursen T, Hansen B, Fisker S. Pain perception after subcutaneous injections of media containing different buffers. Basic Clin Pharmacol Toxicol. 2006 Feb;98(2):218-21. PubMed, CrossRef
  25. Yu AW, Leung CB, Li PK, Lui SF, Lai KN. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. Int J Artif Organs. 1998 Jun;21(6):341-3. PubMed, CrossRef
  26. Gely C, Marin L, Gordillo J, Mañosa M, Bertoletti F, Cañete F, Gonzalez-Muñosa C, Cabré E, Domènech E, Garcia-Planella E. N032 Impact of pain due to subcutaneous administration of a biological drug. J Crohn’s Colitis. 2018; 12(Suppl 1):S582-583.  CrossRef
  27. Fukaya M, Ito A. A New Economic Method for Preparing Platelet-rich Plasma. Plast Reconstr Surg Glob Open. 2014 Jul 9;2(6):e162.  PubMed, PubMed, CrossRef
  28. Biloklytska GF, Kopchak OV, Dieiev VA, Rozdobudko NI. New algorithm of injection PRP-therapy in parodontology. J Educ Health Sport. 2017;7(10):198-206.
  29. Truss NJ, Armstrong PC, Liverani E, Vojnovic I, Warner TD. Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. J Thromb Haemost. 2009 Nov;7(11):1897-905.  PubMed, CrossRef
  30. Greinacher A. Platelet activation by heparin. Blood. 2011 May 5;117(18):4686-7. PubMed, CrossRef
  31. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. Blood. 2011 May 5;117(18):4946-52. PubMed, PubMedCentral, CrossRef
  32. Buechler KF, Nakamura KK. More on troponin assays and heparin. Clin Chem. 2001 Jan;47(1):144-7. PubMed
  33. Kramer ME, Keaney TC. Systematic review of platelet-rich plasma (PRP) preparation and composition for the treatment of androgenetic alopecia. J Cosmet Dermatol. 2018 Oct;17(5):666-671. PubMed, CrossRef
  34. Data for biochemical research (third edition) by Dawson RM, Elliott DC, Elliott WH, Jones KM. pp 580. Oxford Science Publications, OUP, Oxford, 1986. ISBN 0‐19‐855358‐7 – Wood – 1987 – Biochemical Education – Wiley Online Library.
  35. Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent. 2001;10(4):225-8. PubMed, CrossRef
  36. Oudelaar BW, Peerbooms JC, Huis In ‘t Veld R, Vochteloo AJH. Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature. Am J Sports Med. 2019 Feb;47(2):479-487. PubMed, CrossRef
  37. Downing SR, Klement GL. Isolation and proteomic analysis of platelets by SELDI-TOF MS. Methods Mol Biol. 2012;818:153-70. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.